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Insulin resistance, hyperinsulinemia, and hyperproinsulinemia oc-
cur early in the pathogenesis of type 2 diabetes (T2D). Elevated
levels of proinsulin and proinsulin intermediates are markers of
β-cell dysfunction and are strongly associated with development
of T2D in humans. However, the mechanism(s) underlying β-cell
dysfunction leading to hyperproinsulinemia is poorly understood.
Here, we show that disruption of insulin receptor (IR) expression in
β cells has a direct impact on the expression of the convertase
enzyme carboxypeptidase E (CPE) by inhibition of the eukaryotic
translation initiation factor 4 gamma 1 translation initiation com-
plex scaffolding protein that is mediated by the key transcription
factors pancreatic and duodenal homeobox 1 and sterol regulatory
element-binding protein 1, together leading to poor proinsulin
processing. Reexpression of IR or restoring CPE expression each
independently reverses the phenotype. Our results reveal the
identity of key players that establish a previously unknown link
between insulin signaling, translation initiation, and proinsulin
processing, and provide previously unidentified mechanistic in-
sight into the development of hyperproinsulinemia in insulin-
resistant states.
ER stress | prohormone | bIRKO | GWAS
Elevated proinsulin and processing intermediates in the cir-culation of patients with type 2 diabetes (T2D) suggest a
defect in hormone processing in β-cell secretory granules (1–3).
Genome-wide association studies have recently identified several
SNPs in or near the TCF7L2, SLC30A8, SGSM2, VPS13C,
MAPK-activating death domain (MADD), and ADCY5 genes
that are associated with either altered proinsulin levels or pro-
insulin-to-insulin conversion (4–6). These findings gain signifi-
cance because an increase in the proinsulin-to-insulin ratio
predicts future development of T2D in apparently healthy indi-
viduals (7, 8). Given that proinsulin has only ∼5% of the
biological activity of mature insulin, an increase in circulating
proinsulin is predicted to limit the actions of mature insulin and,
consequently, to contribute to worsening glucose tolerance in
humans (9). Other studies have reported increased circulating
proinsulin in insulin-resistant obese subjects with normal glucose
tolerance compared with nonobese individuals (10, 11), sug-
gesting a potential role for insulin resistance in proinsulin pro-
cessing. However, the precise molecular mechanisms underlying
β-cell dysfunction that promote hyperproinsulinemia remain poorly
understood.
The biosynthesis of insulin is regulated at multiple levels, in-
cluding transcription as well as posttranslational protein folding
at the endoplasmic reticulum (ER) and proteolytic cleavage and
modification of the properly folded proinsulin in the secretory
granules by prohormone convertase (PC) 1/3, PC2, and car-
boxypeptidase E (CPE) (12–16). However, the effects of insulin
signaling on posttranslational processing of insulin are not fully
explored.
In addition to insulin’s actions in classical insulin-responsive
tissues (muscle, liver, and fat), insulin signaling regulates β-cell
mass and function (17–22), as well as transcription of the insu-
lin gene itself (23). We hypothesized that disruption of normal
growth factor (insulin) signaling in the β cell has an impact on
proinsulin processing and/or adversely affects the function of the
ER and, ultimately, the β cell. In this study, to examine whether
disruption of the insulin-signaling pathway has a direct impact on
proinsulin content, we examined the pancreas and islets from
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mice with insulin receptor knockout in the β cells (βIRKO), a
mouse model manifesting a phenotype that resembles human
T2D (19), and we also investigated β-cell lines lacking the insulin
receptor (IR) (20). We have previously reported that βIRKO
mice developed age-dependent, late-onset T2D (19) with an in-
crease in the ratio of circulating total insulin to C-peptide suggesting
elevated proinsulin secretion by βIRKO cells. However, the
potential contribution of proinsulin in the development of T2D
remains unknown.
We demonstrate an increased accumulation of proinsulin in
the βIRKO cells due to altered expression of PC enzymes, es-
pecially CPE. These changes are mediated by duodenal ho-
meobox protein (Pdx1) and sterol regulatory element-binding
protein 1 (SREBP1) transcriptional regulation of the translation
initiation complex scaffolding protein, eukaryotic translation
initiation factor 4 gamma (eIF4G) 1, and indicate a previously
unidentified role for these transcription factors in the regulation
of translational initiation. Reexpression of the IR in the βIRKO
cells, knocking down proinsulin, or maintaining normal expres-
sion of CPE each independently restores the normal phenotype
in mutant β cells. Together, these data point to previously un-
identified links between insulin signaling, translational initiation,
and proinsulin processing.
Results
Lack of IRs in β Cells Promotes Proinsulin Accumulation. To in-
vestigate the role of proinsulin in the development of diabetes in
βIRKO mice, we performed longitudinal studies in control and
βIRKO male mice fed a chow diet from the age of 2–7 mo. We
observed that both control and βIRKO mice at the age of 4 mo
exhibited an increase in the proinsulin/insulin ratio compared
with their respective levels at 2 mo, despite unaltered fed blood
glucose levels (Fig. 1A), and argue against the primary role of
glucose in the modulation of proinsulin levels. Interestingly, we
also observed that βIRKO mice manifested a much greater el-
evation in the proinsulin/insulin ratio beginning at the age of
4 mo until the end of the study, which was accompanied by ele-
vated blood glucose when the mice were 5 mo old (Fig. 1A). Our
data indicate that impaired insulin signaling in β cells increases
circulating proinsulin and, notably, occurs before the onset
of hyperglycemia. These data provide an association between
hyperproinsulinemia and the development of T2D in the β-cell
insulin signaling-deficient βIRKO model and prompted us to
examine the direct role of insulin signaling in proinsulin processing
in the β cells. Considering that the IR substrate-2 knockout
(IRS2KO) mouse (24) phenocopies the βIRKO mouse, it is worth
exploring whether the higher circulating insulin immunoreactivity
in the former is also due, in part, to higher proinsulin levels.
To confirm that the elevated proinsulin is indeed derived from
β cells, we examined the pancreas from control and βIRKO mice.
Immunohistochemical analyses revealed high levels of proinsulin
in a significantly greater number of β cells from the βIRKO mice
compared with controls (Fig. 1B). Consistent with these data,
cellular content of proinsulin and the proinsulin/insulin ratio
were also significantly higher in the βIRKO islets, as determined
by ELISA and HPLC (Fig. 1C and Fig. S1A). Furthermore,
consistent with the observations in primary islets isolated from
the βIRKO mice, β-cell lines lacking the IR (βIRKO) (20) also
exhibited a significantly higher proinsulin/insulin ratio and pro-
insulin content (Fig. 1D and Fig. S1B). Based on these data, and
given the limitations of using primary islets for mechanistic
experiments, we focused on studying βIRKO cell lines.
To evaluate dynamic alterations in processing, we transfected
control or βIRKO cell lines with an insulin–C-peptide–GFP con-
struct. Western blotting of lysates from control cells, obtained 48 h
after transfection, revealed the presence of proinsulin-GFP (Fig. 1E;
40 kDa), a fully cleaved C-peptide–GFP band (Fig. 1E; 30 kDa), and
intermediate bands likely to be partially processed A or B chains
attached to C-peptide GFP. In the βIRKO cells, we also observed the
proinsulin-GFP precursor; however, in marked contrast to the con-
trols, we detected significantly reduced fully cleaved C-peptide–GFP
and also partially processed proinsulin-GFP intermediates, confirm-
ing poor processing of proinsulin. To investigate the underlying cause
of poor proinsulin processing in βIRKO cells, we evaluated the ex-
pression pattern of the proinsulin processing enzymes PC1/3, PC2,
and CPE. In both the cell line (Fig. 1F) and islets (Fig. S1C), we
observed a significant decrease in the expression of processing
enzymes, with the most striking reduction evident in the expression of
CPE. Interestingly, we also observed a similar down-regulation of
CPE protein in islets isolated from C57BL/6J mice fed a high-fat diet
(HFD) (Fig. 1G), which is a commonly used T2D mouse model, as
well as in primary human islets isolated from patients with T2D
Fig. 1. Increase in proinsulin due to down-regulation of CPE in β cells
lacking IRs. (A) Blood glucose and circulating proinsulin-to-insulin ratio in
control (Con) or βIRKO mice aged 2–7 mo (n = 5–9). (B) Immunostaining and
quantification for proinsulin (green), insulin (red), and DAPI (blue) in pan-
creas sections from control or βIRKO mice (n = 4–5). (Scale bar, 50 μm.) (C)
Proinsulin-to-insulin ratio measured with ELISA and proinsulin content
measured by HPLC in islets isolated from control or βIRKO mice using ELISA
(n = 5–6). (D) Proinsulin-to-insulin ratio measured with ELISA in control or
βIRKO cell lines (n = 4). (E) Western blotting for C-peptide–GFP in a control
or βIRKO cell line expressing a preproinsulin-GFP expression construct (arrow
points to C-peptide–GFP; n = 3 per group). (F) Western blotting for PC1/3,
PC2, CPE, or tubulin (loading control) in a control or βIRKO cell line (n = 4).
(G) Representative Western blotting for CPE, PC1/3, or tubulin (loading
control) in islets (pooled) isolated from control or HFD-fed C57BL/6J mice
(n = 6). (H) Representative Western blotting for CPE, PC1/3, or tubulin (loading
control) in islets isolated from controls or patients with T2D (n = 5). (I) Pro-
insulin-to-insulin ratio measured with ELISA and Western blotting for CPE or
proinsulin in control, βIRKO, or β-CPE–reexpressing (Re-Exp) cell lines (n = 4).
**P < 0.01 (vs. control); #P < 0.05 (vs. βIRKO). (J) Western blotting for pro-
insulin, PC1/3, PC2, CPE, or tubulin (loading control) in control, βIRKO, mock, or
Re-Exp β-cell lines (n = 3). (K) Proinsulin-to-insulin ratio measured with ELISA in
control, βIRKO, mock, or Re-Exp β-cell lines (n = 4 per group). *P < 0.05; **P <
0.01; ***P < 0.001. Data are mean ± SEM.
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(Fig. 1H). Thus, the processing defect in the mutant β cells is asso-
ciated with reduced expression of proinsulin-processing enzymes
and is consistently observed in both primary T2D human and
mouse islets.
Next, to explore the effects of restoring CPE levels, we tran-
siently reexpressed CPE in the βIRKO cells and observed that
the proinsulin/insulin ratio and proinsulin content were restored
to control levels, as shown by both ELISA and Western blotting
analyses (Fig. 1I and Fig. S1D). Thus, our results demonstrated
that the proinsulin-processing defect is largely due to the down-
regulation of CPE in the βIRKO cells. We subsequently
examined the role of insulin signaling in the regulation of pro-
insulin-processing enzymes and proinsulin levels in βIRKO cells,
by stably reexpressing the human IR B isoform (exon 11+) in the
mutant β cells (23) (Fig. S1E), and observed that the expression
of PC1/3 and CPE, as well as proinsulin levels, reverted to
control levels (Fig. 1J). Consistently, the proinsulin/insulin ratio
was also restored (Fig. 1K).
Altered Expression of Proinsulin-Processing Enzymes in β Cells from
βIRKO Mice. To examine if insulin signaling directly modulates the
expression of the processing enzymes, we stimulated control or
βIRKO cells with exogenous insulin. CPE protein expression was
up-regulated by insulin stimulation in control cells in contrast to
a blunted response in the βIRKO cells (Fig. 2A), confirming that
insulin signaling directly modulates the expression of CPE. A
previous study has shown that transcription of CPE is positively
regulated by insulin via FoxO1 in the proopiomelanocortin
(Pomc)-expressing neurons (25). To investigate whether CPE is
indeed regulated by a similar mechanism in β cells, we were
surprised to observe that the CPE transcripts showed a trend
toward compensatory up-regulation in the βIRKO cells instead
of a decrease, as one would predict from the protein expression
level and from the previous study (25) (Fig. S2 A and B). These
data suggest that the down-regulation of CPE protein is medi-
ated by a transcription-independent regulation in the β cells by
insulin. Further, we confirmed that the observed down-regula-
tion of CPE protein in the βIRKO cells is not due to altered
stability of either the CPE transcript or protein (Fig. S2 C and D)
in contrast to the previously reported CPE regulation by pal-
mitate exposure (26). Therefore, these data indicated that CPE
is translationally regulated by insulin in the β cells. Indeed, the
pulse-labeling analyses revealed reduced biosynthesis of CPE in
the βIRKO cells (Fig. 2B). To assess the direct regulation of IR
signaling on proinsulin-processing enzymes further, especially
CPE protein expression, we transiently knocked down the IR in
the control cells by infection of shRNA-expressing lentivirus
against the IR and examined the levels of proinsulin-processing
enzymes over time. The levels of IR began to decrease 32 h after
infection and were accompanied by a decrease in CPE protein,
but not CPE mRNA, and did not affect PC1/3 or PC2 protein
levels (Fig. 2C and Fig. S3A).
At this point, we considered previous reports that have shown
protein biosynthesis is tightly regulated by ER homeostasis (27,
28), and, interestingly, we observed that chronic absence of in-
sulin signaling in the βIRKO cells up-regulates ER stress (Fig.
2D and Fig. S3B). To determine whether the down-regulation of
CPE biosynthesis is a consequence of ER stress in the βIRKO
cells, we examined the cells with acute IR knockdown and failed
to detect significant changes in ER stress markers before the
decrease of CPE after IR knockdown, suggesting that the down-
regulation of CPE protein is directly regulated by insulin sig-
naling and is independent of ER stress (Fig. S3C). Further, we
observed that knocking down proinsulin or reexpressing CPE or
IR in βIRKO cells completely alleviated ER stress (Fig. 2E and
Fig. S4 A–E), suggesting that dysfunctional proinsulin processing
potentially regulates the ER stress response in β cells. However,
we cannot completely rule out the role of ER stress on CPE
protein biosynthesis in βIRKO cells secondary to long-term in-
sulin signaling deficiency. Thus, our data confirm a direct role for
insulin signaling in CPE protein biosynthesis.
To assess the translational effects of IR KO on CPE tran-
scripts, we performed polyribosomal profiling of total RNA (29).
Fig. 2F shows the position of the 80S ribosomal species, as well
as the polyribosomes from the RNA isolated from control or
βIRKO cells. The ratio of polyribosomes to 80S monosomes
(P/M ratio) tended to be lower in the βIRKO cells, suggesting
Fig. 2. Insulin signaling regulates CPE translation initiation. (A) Western
blotting for proinsulin, PC1/3, CPE, and tubulin (loading control) in control or
βIRKO cell lines with or without exogenous insulin stimulation (10 nM) for
12 h. (B) Western blotting for CPE or tubulin in control or βIRKO cell lines after
pulse labeling with modified methionine and then harvesting at the in-
dicated time points. (C) Western blotting for IR, CPE, PC1/3, PC2, or tubulin
(loading control) in control or IR knockdown (KD) β cells harvested 24, 32, or
44 h after IR shRNA containing lentiviral infection. (D, Left) Quantitative PCR
(qPCR) for mRNA of ER stress markers (BiP, total XBP-1, spliced XBP-1, or
CHOP) in fluorescence-activated cell-sorted β cells from control (open bar) or
βIRKO (gray bar) mice (n = 4). (D, Right) Western blotting for BiP, CHOP,
or tubulin (loading control) in islets isolated from control or βIRKO mice and in
control or βIRKO cell lines (n = 3). (E, Left) qPCR for mRNA of ER stress
markers (BiP, total XBP-1, spliced XBP-1, and CHOP) in control, βIRKO, or
βIRKO proinsulin KD cell lines (n = 4 per group). A.U., arbitrary units. (E,
Right) Western blotting for p-IRE1α, total IRE1α, BiP, CHOP, and tubulin
(loading control) in control, βIRKO, or βIRKO proinsulin KD cell lines (n = 3
per group). (F, Left) Translational profiling of control or βIRKO cells. Profiles
through the gradient were measured by A254. Positions of the 40S and 80S
subunits, 80S monosome, and polyribosomes are indicated. Data shown are
from representative experiments performed on three occasions. (F, Right)
Polysome/monosome (P/M) ratios for the translational profiles of control or
βIRKO cells (n = 3). (G) Real-time qPCR for insulin, CPE, PC1/3, or PC2 mRNA
extracted from pooled monosome or polysome fractions of control or βIRKO
cells (n = 3). Data are mean ± SEM. *P < 0.05 (vs. control); **P < 0.01 (vs. control);
#P < 0.05 (vs. βIRKO); ##P < 0.01 (vs. βIRKO).

















a relative dissipation of the polysome fraction (Fig. 2F). The
decrease in polysomes, as reflected in the lower P/M ratio, is
characteristic of a block in translational initiation (30). To con-
firm the block at the transcript level, we analyzed the mRNAs
contained in the pooled monosome (nontranslating) and poly-
some (actively translating) fractions in both control and βIRKO
cells. Insulin mRNA preferentially partitioned into polysomes in
both cell types (Fig. 2G), suggesting that insulin mRNA is actively
translated. Consistently, CPE mRNA is also preferentially par-
titioned into the polysome fraction in the control cells; how-
ever, in contrast, CPE mRNA in the βIRKO cells was observed
to partition equally into monosome and polysome pools, sug-
gesting relative translation initiation blockade for CPE. Notably,
we did not observe a similar block in translation initiation for the
mRNAs encoding PC1/3 and PC2 (Fig. 2G). We observed an
unaltered mRNA partitioning for insulin mRNA, which is the
most abundant transcript in β cells and other processing enzymes
(PC1/3 and PC2). Thus, our data argue for a selective trans-
lational initiation regulation of the proinsulin-processing enzyme,
CPE, but against a global down-regulation of translation initia-
tion in the βIRKO cells as suggested by the low P/M ratio.
Insulin Signaling Directly Regulates the Translation Initiation Complex
to Have an Impact on CPE Translation. To investigate further how
insulin regulates the translational process and to identify its
translational targets in β cells, we examined the expression pattern
of multiple proteins involved in the regulation of protein trans-
lation, some of which have been reported to be regulated by insulin
signaling, including those in the mammalian target of rapamycin
(mTOR) signaling pathways and translation initiation complexes
(31). Although a majority of the proteins, including those in the
mTOR signaling pathway, such as the 4EBP and eIF2a proteins
and most translation initiation complex proteins, were unaffected
(Fig. S5A), the translation initiation scaffolding proteins eIF4G1
and eIF4G2 were altered only in the βIRKO cells but not in
controls (Fig. 3A). Indeed, in support of a direct effect of insulin,
the decrease in expression of IR after knockdown was accompa-
nied by a down-regulation of eIF4G1 as early as 32 h followed later
by a decrease in eIF4G2, suggesting secondary regulation of the
latter protein by insulin signaling (Fig. 3B). Similar to the obser-
vation in βIRKO cells, we observed no significant changes in
proteins in the mTOR signaling pathway or translation initiation
complexes in cells with acute knockdown of the IR, confirming
a specific regulation of eIF4G1 by insulin signaling (Fig. S5B).
More importantly, we detected down-regulation of eIF4G1 in islets
from HFD mice (Fig. 3C) and islets from patients with T2D (Fig.
3D), confirming the pathophysiological relevance of our observa-
tions. Transient reexpression of eIF4G1 restored the protein level
of CPE and the proinsulin-to-insulin ratio, confirming the role of
eIF4G1 in the regulation of CPE protein level in βIRKO cells and
mouse islets isolated from obese ob/ob mice (Fig. 3 E and F).
The efficiency of translation initiation is greatly affected by the
mRNA 5′ untranslated region (UTR) harboring a high degree of
secondary structure characterized by a high guanine cytosine
(GC) content and thermostability [low delta G (dG)] (32). To
investigate the mechanism underlying the specific regulation of
CPE but not PC1/3 protein expression via down-regulation of
eIF4G1 in the insulin signaling-deficient β cells, we examined the
5′ UTR of both CPE and PC1/3 mRNA. Interestingly, despite
similarities in length, the 5′ UTR of CPE is relatively GC-rich
(71.4% vs. 48%) and has higher free energy (dG = −39.64 vs.
−17.13), as determined by UNAFold (33), compared with the 5′
UTR of PC1/3 (Fig. 3G). These data predict that the 5′ UTR of
the CPE can form a more stable secondary stem loop structure
that is subjected to translational initiation regulation compared
with PC1/3. This is because eIF4G1 acts as a core scaffolding
protein for the critical translation initiation complex, eIF4F, that
mediates the initiation of cellular mRNA translation (34). For
example, in the case of CPE, down-regulation of eIF4G1 in
βIRKO is expected to reduce the activity of the eIF4F complex,
rendering the mRNA with relative highly structured 5′ UTR to
translational initiation inhibition. To confirm the role of CPE 5′
UTR on the expression of CPE further, we fused the CPE and
PC1/3 open reading frames (ORFs) with PC1/3 and CPE 5′
UTR, respectively. To distinguish exogenously expressed CPE
and PC1/3, the ORFs were tagged with FLAG or V5 epitopes,
respectively. We observed that the V5-tag PC1/3 with CPE 5′
UTR is overexpressed in the control cells but is down-regulated
upon knockdown of the IR, as demonstrated by immunoblotting
for PC1/3 (detects both endogenous and exogenous PC1/3) and
V5 (detects exogenous PC1/3) (Fig. 3H, Left). Consistently, we
also observed down-regulation of the endogenous level of CPE
in the cells with knockdown of the IR (Fig. 3H, Left). Similarly,
the FLAG-tagged CPE with PC1/3 5′ UTR is overexpressed in
the control cells but remains unchanged after knockdown of IR,
as shown by the FLAG immunoblot (Fig. 3H, Right). Reduced
CPE levels shown by the CPE immunoblot (detects both en-
dogenous and exogenous CPE) are contributed by the reduction
of endogenous CPE upon IR knockdown (Fig. 3H, Right), and
Fig. 3. Insulin signaling regulates the translation initiation complex to
modulate CPE translation. (A) Western blotting for eIF4G1, eIF4G2, eIF4A1,
polyadenylate-binding protein 1 (PABP1), eIF4E, eIF4B, or tubulin (loading
control) in control or βIRKO cell lines under basal conditions (n = 3). (B)
Western blotting for eIF4G1, eIF4G2, or tubulin (loading control) in control
or IR KD β cells harvested 24, 32, or 44 h after IR shRNA containing lentiviral
infection. (C) Representative Western blotting for eIF4G1 or tubulin (loading
control) in islets (pooled) isolated from control or HFD-fed C57BL/6J mice
(n = 6). (D) Representative Western blotting for eIF4G1 or tubulin (loading
control) in islets isolated from controls or patients with T2D (n = 5). (E)
Western blotting for CPE, eIF4G1, and tubulin (loading control) in control,
βIRKO, or βIRKO eIF4G1-reexpressing cell lines. (F) Western blotting for CPE,
eIF4G1, and tubulin (loading control) (Left) and proinsulin ELISA (Right) in
islets isolated from lean control or obese ob/ob mice with or without eIF4G1
reexpression. (G) Length, percentage of GC, dG of CPE, or PC1/3 5′ UTR was
analyzed with UNAFold. (H, Left) Western blotting for PC1/3, V5, CPE, or
tubulin (loading control) in control, V5 tag-PC1/3 with CPE 5′ UTR, or V5-tag
PC1/3 with CPE in IR KD cells. (H, Right) Western blotting for CPE, FLAG, PC1/3,
and tubulin (loading control) in control, FLAG-tag-CPE with PC1/3 5′ UTR,
or FLAG tag-CPE with PC1/3 5′ UTR in IR KD cells.
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endogenously expressed PC1/3 consistently showed no change.
Taken together, our data demonstrate that insulin signaling
directly modulates the key proinsulin-processing enzyme, CPE,
by regulating the translational initiation complex scaffolding
protein, eIF4G1.
Transcription Factor Pdx1 Regulates eIF4G1 in Pancreatic β Cells. To
investigate the underlying molecular mechanism(s) regulating
the level of eIF4G1, we focused on the significant decrease in its
gene expression in both βIRKO cells and primary islets (Fig. 4A),
which suggested that eIF4G1 is transcriptionally regulated.
These alterations were confirmed in primary HFD mouse islets
(Fig. 4B) and T2D human islets (Fig. 4C). Next, using in silico
sequence analyses, we identified putative binding sites for the
pancreatic and duodenal homeobox protein, Pdx1, a critical
transcription factor for β-cell survival and function, in the pro-
moter of the murine eIF4G1 gene (Fig. S6A). Consistent with
our previous report (17), Pdx1 was down-regulated in both the
β-cell line and primary islets isolated from βIRKO mice (Fig.
4D), as well as in HFD mouse islets (Fig. 4E) and T2D human
islets (Fig. 4F). To confirm the role of Pdx1 on eIF4G1 regula-
tion, we examined previously published Pdx1 ChIP sequencing
data (35) and observed that Pdx1 binding is enriched at the 5′
region of the eIF4G1 gene locus in both mouse and human
primary islet samples (Fig. S6B). This observation was confirmed
by Pdx1 ChIP on primary mouse islets, where we detected an
approximately fivefold enrichment of Pdx1 binding on both
the 5′ and 3′ regions of the eIF4G1 gene (Fig. 4G). Taken together,
our data so far suggest that Pdx1 modulates eIF4G1 gene ex-
pression via binding at the promoter and potential 3′ enhancer
region in β cells and that this regulation is conserved in human
islets, as demonstrated in the ChIP-sequencing data. Further
experiments that address effects of mutational analyses of the
Pdx1 binding site would be necessary to provide evidence for
direct regulation of the eIF4G1 gene.
Next, to determine the role of Pdx1 in the regulation of
eIF4G1, we transiently reexpressed Pdx1 in the βIRKO cells and
mouse islets isolated from obese ob/ob mice. Real-time PCR,
Western blot, and proinsulin ELISA analysis revealed that Pdx1
reexpression only partially restored the expression of eIF4G1 but
completely restored the proinsulin-to-insulin ratio (Fig. 4 H and
I), suggesting an additional regulator of eIF4G1 other than Pdx1
in βIRKO cells. To confirm this possibility, we performed acute
knockdown of the IR in control cells and observed that Pdx1
expression was significantly down-regulated 44 h after infection
(Fig. 4J) and occurred later than down-regulation of eIF4G1
(Fig. 3B).
Transcription Factor SREBP1 Regulates eIF4G1 in Pancreatic β Cells.
To identify the additional regulator of eIF4G1, we again ana-
lyzed the promoter region of the murine eIF4G1 gene and de-
tected multiple SREBP1 transcription factor binding sites (Fig.
5A) that were highly conserved between murine and human ortho-
logs (Fig. S7A). Indeed, overexpression or activation of SREBP1 has
been implicated in the down-regulation of key β-cell genes, including
Pdx1, in addition to modulating β-cell function (36, 37). A potential
role for SREBP1 in our studies was confirmed by a significant in-
crease in mature SREBP1 in both β-cell lines and primary islets from
βIRKO mice (Fig. 5B), as well as in primary islets from HFD mice
and humans with T2D (Fig. 5C). A similar increase in mature
SREBP1 in the control cells with acute knockdown of the IR (Fig.
5D) suggested direct regulation of SREBP1 by insulin signaling. To
confirm the impact of SREBP1 on eIF4G1 expression, we per-
formed acute knockdown of SREBP1 in βIRKO cells. Transient
knockdown of SREBP1 (∼70%) fully restored the expression of
eIF4G1 in the βIRKO cells (Fig. 5E). Further, knockdown of
SREBP1 also restored the expression of Pdx1 in the βIRKO cells
(Fig. 5E, Lower), confirming a role for SREBP1 in regulating Pdx1
expression (36). Taken together, our data reveal that in the β cells,
insulin signaling regulates translation initiation by regulating the
level of eIF4G1 via SREBP1 and Pdx1.
To investigate how insulin up-regulates mature SREBP1 in
βIRKO cells, we examined the transcription of the full-length
SREBP1 and the SREBP1 interacting partners, because tran-
scriptionally active SREBP1 requires processing at the ER and
Golgi, which, in turn, is regulated by the availability of its in-
teracting partners, the sterol regulatory element-binding pro-
tein cleavage-activating protein (SCAP) and insulin-induced
gene (Insig) proteins, at the ER (38). Consistently, the SREBP1
gene expression was also up-regulated in the βIRKO cells (Fig.
5F), as well as in HFD mouse islets and T2D human islets (Fig.
5G). Further, the gene and protein expression of SCAP was up-
regulated in both the βIRKO cells and islets (Fig. 5 H and I).
Interestingly, we observed an increase in the gene expression of
Insig1 and Insig2 in the βIRKO cells but a decrease in its protein
levels in both the βIRKO cells and isolated islets (Fig. 5 H and I).
Fig. 4. Insulin signaling regulates eIF4G1 via Pdx1. (A) Real-time qPCR for
eIF4G1 in control or βIRKO cell lines and in islets isolated from control or
βIRKO mice (n = 4). Data are mean ± SEM. *P < 0.05; **P < 0.01. (B) qPCR for
eIF4G1 in islets isolated from control or HFD-fed C57BL/6J mice (n = 6). Data
are mean ± SEM. *P < 0.05. (C) qPCR for eIF4G1 in islets isolated from
controls or patients with T2D (n = 5). Data are mean ± SEM. *P < 0.05. (D)
qPCR (Left) and Western blotting (Right) for Pdx1 in control or βIRKO cell
lines and in islets isolated from control or βIRKO mice (n = 4). Data are mean ±
SEM. *P < 0.05. (E) qPCR (Upper) and representative Western blotting
(Lower) for Pdx1 in islets (pooled) isolated from control or HFD-fed C57BL/6J
mice (n = 6). Data are mean ± SEM. *P < 0.05. (F) qPCR (Left) and repre-
sentative Western blotting (Right) for Pdx1 in islets isolated from controls or
patients with T2D (n = 5). Data are mean ± SEM. *P < 0.05. (G) ChIP assay for
Pdx1 on eIF4G1 5′ and 3′ regions in primary mouse islets. Data are mean ±
SEM. *P < 0.05. (H) qPCR (Left) for eIF4G1 and Western blotting (Right) for
eIF4G1, Pdx1, and tubulin (loading control) in control, βIRKO, or βIRKO Pdx1-
reexpressing cell lines. (I) Western blotting for CPE, eIF4G1, Pdx1, and tubulin
(loading control) (Left) and proinsulin ELISA (Right) in islets isolated from
lean control or obese ob/ob mice with or without Pdx1 reexpression. (J)
Western blotting for Pdx1 or tubulin (loading control) in control or IR KD β
cells harvested 24, 32, or 44 h after IR shRNA containing lentiviral infection.

















This observation is consistent with a previous study (39), which
reported that degradation of Insig1, a protein with a short t1/2, is
accelerated in cells with induced ER stress such as occurs in the
βIRKO cells (Fig. S3B). Up-regulation in Insig1 mRNA is likely
a compensatory response for the reduced protein levels in the
ER. Taken together, our observations indicate that an increase
in mature SREBP1 in βIRKO cells and islets is potentially due to
an increase in SREBP1 and SCAP expression, and is facilitated
by the down-regulation of Insig1 protein.
From the literature, it is evident that insulin potently stim-
ulates SREBP1 gene expression via a “feed-forward” mechanism
in the liver (40, 41). However, in this study, interestingly, we
observed an up-regulation of SREBP1 gene expression in the
β cells despite the absence of functional IRs. This observation
is analogous to the pathophysiological phenomenon wherein
SREBP1 is up-regulated in insulin-resistant hepatocytes (42);
however, this has not, to our knowledge, been described in the
pancreatic β cell. To investigate the potential mechanism un-
derlying our observation, we examined insulin signaling in the
βIRKO cells. Under basal conditions, we observed an increase in
phospho-ERK with unchanged phospho-Akt (Fig. 5J and Fig.
S7B), which is probably due to a compensatory up-regulation of
insulin-like growth factor 1 receptors (IGF1Rs) in the IR-
deficient β-cell line, a finding we have reported previously (18,
20). These data suggest that up-regulation of the ERK pathway
in the βIRKO cell is sufficient to restore specific insulin signaling
functions that are especially relevant for the regulation of SREBP1
expression. We also observed an increase in the gene and protein
expression of IR substrate-1 (IRS1) and a decrease in IRS2 mRNA
but unchanged IRS2 protein levels in the βIRKO cells (Fig. 5 J and
K). Indeed, previous studies in the liver have reported that IRS1,
but not IRS2, is positively correlated with the expression of
SREBP1c (43) and that insulin acts via IRS1 to stimulate SREBP1-
regulated lipogenic genes in the liver (44). Our results demonstrate
that in the insulin signaling-deficient β cells, a selective up-regu-
lation of IRS1 leads to an increase in SREBP1 and a subsequent
decrease in Pdx1 protein that ultimately inhibits proinsulin pro-
cessing by suppressing translation initiation.
Discussion
Elevated levels of proinsulin and proinsulin intermediates are
features of T2D (2) and are strongly associated with impaired
β-cell function and development of the disease in humans (45,
46). In this study, we report a novel link between IR growth
factor signaling, translational initiation, and proinsulin process-
ing in pancreatic β cells.
Previously, we have reported that insulin signaling affects
β-cell proliferation, survival, and secretory function (reviewed in
ref. 22). An increase in circulating proinsulin in the βIRKO mice
led us to hypothesize that insulin signaling regulates proinsulin
processing. Our finding on proinsulin accumulation in β cells
lacking IRs is similar to that in mice with KO of the individual
proinsulin-processing enzymes PC1/3, PC2, or CPE, all of which
exhibit increased circulating proinsulin (47–50). Higher circu-
lating proinsulin in βIRKO mice and increased proinsulin con-
tent in βIRKO cells are due to defective proinsulin processing
secondary to a decrease in the eukaryotic initiation factor eIF4G1
and subsequent down-regulation of CPE biosynthesis. Higher
circulating proinsulin in βIRKO mice could potentially be due to
an increase in the constitutive secretory pathway in βIRKO cells,
because CPE has been shown to function as a prohormone sorting
receptor (51). Down-regulation of CPE in βIRKO cells could
potentially fail to direct proinsulin to the regulated secretory
pathway; however, an increase in circulating proinsulin in βIRKO
mice was accompanied by an increase in proinsulin content in
βIRKO cells, which argues against a role for the constitutive se-
cretory pathway.
The decrease in CPE levels in the βIRKO islets and cells is
consistent with an increase in circulating split proinsulin in-
termediate in patients with T2D (45). Suppressed CPE expres-
sion, due to a significant alteration in protein biosynthesis, was
particularly dramatic in the βIRKO cells, which demonstrated
specific partitioning of CPE mRNA into monosomes. Our
finding is in contrast to that of a previous study showing that
CPE protein in β cells is down-regulated by palmitate exposure via
a mechanism involving protein degradation (26). Because insulin
resistance and dyslipidemia are both risk factors for T2D, bio-
synthesis and stability of CPE could be one of the key regulatory
Fig. 5. Insulin signaling regulates eIF4G1 via SREBP1. (A) Schematic depicts
putative SREBP1 binding sites on eIF4G1 promoter. (B) Western blotting for
mature SREBP1 or tubulin (loading control) in control or βIRKO cell lines and
in islets isolated from control or βIRKO mice (n = 3). (C) Representative
Western blotting for mature SREBP1 or tubulin (loading control) in islets
(pooled) isolated from control or HFD-fed C57BL/6J mice (n = 6) (Left) or
from controls or patients with T2D (n = 5) (Right). (D) Western blotting for
SREBP1 or tubulin (loading control) in control or IR KD β cells harvested 24,
32, or 44 h after IR shRNA containing lentiviral infection. (E) qPCR (Upper)
for eIF4G1 and Western blotting (Lower) for eIF4G1, Pdx1, SREBP1, or tu-
bulin (loading control) in control, βIRKO, or βIRKO SREBP1 KD cell lines. (F)
qPCR for SREBP1a in control or βIRKO cell lines and in islets isolated from
control or βIRKO mice (n = 4). Data are mean ± SEM. *P < 0.05. (G) qPCR for
SREBP1a in islets isolated from control or HFD-fed C57BL/6J mice (n = 6)
(Left) or from controls or patients with T2D (n = 5) (Right). Data are mean ±
SEM. *P < 0.05. (H) qPCR for SCAP (Left), Insig1 (Center), or Insig2b (Right) in
control or βIRKO cell lines and in islets isolated from control or βIRKO mice
(n = 4). Data are mean ± SEM. *P < 0.05; **P < 0.01. (I) Western blotting for
SCAP, Insig1, Insig2, or tubulin (loading control) in control or βIRKO cell lines
and in islets isolated from control or βIRKO mice (n = 3). (J) Western blotting
for IR, IGF1R, phospho-ERK, total ERK, IRS1, IRS2, or tubulin (loading control)
in control or βIRKO cell lines under basal conditions (n = 3). (K) qPCR for IRS1
(Upper) or IRS2 (Lower) in control or βIRKO cell lines and in islets isolated
from control or βIRKO mice (n = 4). *P < 0.05.
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mechanisms modulating CPE levels in β cells in determining the
onset and progression of the disease.
Because mice with mutations in the coding region of the CPE
gene (Cpefat mice) (48) also exhibit alterations in PC1/3 and PC2
expression in the pituitary (52) and processing of other hypo-
thalamic peptides (53), the direct effects of the very low levels of
CPE on expression of PC1/3 in the βIRKO model cannot be
ruled out.
The direct link between insulin signaling, translation initiation,
and processing enzymes is evident by a coordinated down-regulation
of eIF4G1 and CPE upon acute down-regulation of IR in control
β cells. Insulin signaling regulates protein translation via the
mTOR signaling pathway and by phosphorylation of certain
translation initiation proteins (31). It is also known that protein
synthesis is primarily regulated at the translation initiation step
(rather than during elongation or termination), allowing rapid,
reversible, and spatial control of gene expression. This regulation
occurs by means of both the cis-regulatory elements, such as the
5′ and 3′ UTRs, and the transacting factors (54). Thus, the highly
structured UTRs with GC-rich sequences, upstream ORFs, and
internal ribosome entry site could all significantly influence the
rate of translation. A breakdown in this regulatory machinery
could perturb cellular metabolism, leading to significant physi-
ological abnormalities (55, 56).
We show that insulin signaling regulates eIF4G1, leading to
down-regulation of the CPE proinsulin-processing enzyme, which
exhibits a more structured 5′ UTR. eIF4G1 is a core scaffolding
protein for the critical translation initiation complex, eIF4F, that
regulates the translation initiation of mRNAs encoding mito-
chondrial, cell survival, and growth genes in response to diverse
stressors (55). The efficiency of translation initiation is known to
be greatly affected by the complexity of the mRNA 5′ UTR
secondary structures. As such, 5′ UTRs harboring a high degree of
secondary structure (e.g., high GC content) and thermostability
(low dG) are often highly dependent on eIF4F complex trans-
lational activity (32). Down-regulation of eIF4G1 in βIRKO is
expected to reduce the activity of the eIF4F complex.
β cells with a reduced complement of functional IRs exhibit
reduced expression of the homeodomain protein, Pdx1 (17), a
critical transcription factor that regulates β-cell development
and function (57). In this study, we also showed that Pdx1 is
down-regulated in islets from patients with T2D and in primary
islets isolated from HFD mice, a commonly used T2D rodent
model. Identification of Pdx1 binding sites on the promoter re-
gion of the eIF4G1 gene suggested a potential role for Pdx1 in
the expression of eIF4G1. This was confirmed by examination of
previously published Pdx1 cistrome datasets for human and
mouse islets (35) and by Pdx1 ChIP using primary mouse islets.
Indeed, restoration of Pdx1 levels in the βIRKO cells partially
recovered the expression of eIF4G1, suggesting that the home-
odomain protein regulates translational initiation in the IR KO β
cells. This observation led us to identify another transcription
factor in the regulation of translation initiation in the β cell.
SREBP1 is a transmembrane basic helix–loop–helix leucine
zipper family of transcription factor proteins of the ER. It is well
characterized that SREBPs activate the synthesis of fatty acids,
triglycerides, and cholesterol in the liver (38). In contrast, the
role of SREBP in β cells is poorly understood. A limited number
of studies have reported that activation of SREBP1 in β cells is
associated with impaired insulin secretion, enhanced apoptosis,
and suppression of critical genes involved in β-cell function, in-
cluding Pdx1 and IRS2, together leading to β-cell dysfunction
(36). In our study, we observed that expression of both Pdx1 and
IRS2 is down-regulated in the βIRKO cell, which could be due,
in part, to up-regulated SREBP1, because knocking down SREBP1
in the βIRKO cell restored expression of Pdx1.
Despite being regulated by insulin, SREBP1 was reported to
be elevated in insulin resistance in the liver (42). Although the
mechanism underlying this selective insulin resistance is not
completely understood, it has been suggested that the Akt arm of
the insulin signaling pathway, which mediates metabolic effects
of insulin, becomes resistant to insulin, whereas the MAPK arm
remains sensitive (58). Indeed, this is exactly what we observed in
the βIRKO cells. Our observation of selective activation of the
MAPK pathway in insulin-resistant β cells provides a plausible
mechanistic link for a recently identified unusually high linkage
disequilibrium locus, MADD, which was associated with elevated
proinsulin level and impaired proinsulin processing (4–6).
MADD encodes an adaptor protein that plays a role in MAPK
activation (59), suggesting that MAPK activation contributes to
proinsulin processing in β cells. However, we do not rule out the
contribution of a compensatory up-regulation of IGF1R in the
βIRKO cells that may contribute to the findings in selective
hepatic insulin resistance (42, 58). Up-regulation of Insig1 fur-
ther supports the notion of selective insulin resistance in the
βIRKO cell. Our observations of differential regulation of IRS1
vs. IRS2 levels in the βIRKO cells are consistent with a previous
study, which reported that IRS2 is involved in the inhibitory
effects on gluconeogenesis in the liver, whereas IRS1 transduces
stimulatory effects of insulin on de novo lipogenesis, particularly
SREBP1 (44, 60).
The ER plays an important role in insulin biosynthesis, and
properly folded proinsulin is delivered to the Golgi to be pack-
aged into secretory granules for conversion into mature insulin
(61); therefore, ER homeostasis is known to regulate β-cell
function (62). We observed that chronic absence of insulin sig-
naling (e.g., in the βIRKO cell) promotes ER stress, which could
potentially contribute to the up-regulation of proinsulin and
down-regulation of CPE biosynthesis. However, the results from
our acute IR knockdown experiments in control β cells suggest
that the down-regulation of CPE protein is not caused by ER
stress, because no significant changes in ER stress markers were
detected before a decrease in CPE levels after knockdown of the
IR. However, whether CPE is affected by ER stress secondary to
long-term insulin signaling deficiency requires further work.
In summary, we provide evidence that compromised insulin
signaling in pancreatic β cells coordinately regulates Pdx1 and
SREBP1, leading to down-regulation of eIF4G1 and selective
inhibition of CPE translation initiation, which causes defective
proinsulin processing and accumulation of circulating proinsulin
(Fig. 6A). An increase in circulating proinsulin even before the
onset of diabetes in the βIRKO, and potentially in the IRS2KO
mouse (24), suggests that proinsulin is a useful biomarker of
β-cell dysfunction in this model. Our data indicate that these
effects are independent of ER stress, and, importantly, we con-
firm similar molecular defects in primary islets from insulin-
resistant patients with T2D. Whether the molecular defects
proposed in our study contribute directly to the generation of
proinsulin-related peptides (Fig. 6B) and reduced β-cell mass
and whether proinsulin is a reliable biomarker to detect T2D early
in the disease process in humans warrant further investigation.
Methods
Preparation of β-Cell Lines. β-cell lines from βIRKO and control mice were
generated as described previously (19, 20). All protocols were approved by
the Institutional Animal Care and Use Committee of the Joslin Diabetes
Center and Brandeis University and were in accordance with National
Institutes of Health guidelines.
Cell Culture. Cells were maintained in DMEM containing 25 mM glucose
supplemented with 10% (vol/vol) FBS and 100 units/mL penicillin/
streptomycin. Experiments were performed using 80–90% confluent cells.
Islet Isolation and Dispersion. Islets were isolated by the intraductal colla-
genase digestion method, as described previously in 5- to 6-mo-old male mice
(19), in HFD chow-fed C57BL/6J or ob/ob mice obtained from The Jackson
Laboratory. Following overnight culture in RPMI 1640 and 10% (vol/vol) FBS,

















7 mM glucose islets were dispersed after washing in PBS, followed by di-
gestion for 15 min in a 37 °C water bath with 1 mg/mL trypsin (Sigma–
Aldrich) and 30 units/mL DNase. Digestion was stopped by adding cold
DMEM containing 10% (vol/vol) FBS. After several washing steps in PBS, the
cell suspension was filtered. Subsequently, fluorescence-activated cell-sorted
cells were sorted using autofluorescence and size criteria (63) directly into
TRIzol reagent (Invitrogen). The purity of β-cell and non–β-cell fractions was
confirmed by real-time PCR for insulin and glucagon, respectively.
Human Islets. All human islets were obtained from the Southern California
Islet Resources Center. Upon receipt, all human islets were cultured over-
night in Miami Media 1A (Cellgro) before being subjected to experimental
procedures as described below. All protocols were approved by the
Institutional Review Board of the Joslin Diabetes Center.
Immunohistochemistry. Paraffin-embedded pancreas sections were stained
for proinsulin with a mouse monoclonal antibody (gift from Scott Heller,
Novo Nordisk, Copenhagen) used at a 1:100 dilution at 4 °C overnight, fol-
lowed by incubation with FITC-conjugated anti-mouse antibody (1:100 di-
lution, 1 h at room temperature; Jackson Immunoresearch). For insulin,
sections were incubated with antiinsulin antibody (Millipore) at a 1:100 di-
lution overnight (4 °C), followed by incubation with Texas Red conjugated
anti-guinea pig antibody (1:100; Jackson Immunoresearch) for 1 h at room
temperature. Slides were examined under an Olympus BX60 optical micro-
scope or Zeiss LSM 710 microscope under confocal mode.
Proinsulin Quantification from Immunohistochemistry. The number of β cells
expressing proinsulin was scored in at least 1,000 β cells per mouse and three
mice per genotype. The proinsulin-to-insulin cell ratio in controls was arbi-
trarily set at 1.
SDS/PAGE and Western Blotting. Cultured cells were lysed in radioimmunopre
cipitation buffer [150 mM NaCl, 10 mM Tris (pH 7.2), 1% Triton X-100, 1%
deoxycholate, 5 mM EDTA] containing 200 μM orthovanadate and protease
inhibitors (Sigma–Aldrich) (64). Lysates were precleared at 16,000 × g for
15 min at 4 °C, and total protein concentration was determined using bicin-
choninic acid assays (Pierce). Samples were resuspended in reducing SDS/PAGE
sample buffer, boiled, and resolved by SDS/PAGE. Proteins were then trans-
ferred onto nitrocellulose membranes (Schleicher & Schuell), blocked in 5%
(wt/vol) milk in Tris-buffered saline containing 0.1% Tween, and incubated
with primary antibodies overnight at 4 °C. PC1/3 and PC2 antibodies are from
Affinity BioReagents; CPE, Insig1, and tubulin antibodies are from Abcam;
insulin, SREBP1, IR, and IGF1R antibodies are from Santa Cruz Biotechnology;
phospho–inositol-requiring enzyme 1α (pIRE1α) antibody is from Novus Bio-
logicals; IRE1α, immunoglobulin-heavy-chain-binding protein (BiP), cleavage
and total Caspase 3, phospho-Akt, total Akt, phospho-ERK, total ERK, IRS2 and
all translational related antibodies are from Cell Signaling; X-box binding
protein-1 (XBP-1), ATF6, and C/EBP homology protein (CHOP) are from Santa
Cruz Biotechnology. Pdx1 and IRS1 antibodies are from Millipore, and V5 and
Flag antibodies from are GenScript. SCAP antibody is from Proteintech.
For proinsulin processing assays, cells grown in 6-cm plates were lysed in
Laemmli sample buffer, sonicated, and heated at 80 °C for 10 min. After
electrophoresis through an 8–16% (vol/vol) Tris·glycine gel (Invitrogen),
proteins were transferred to a nitrocellulose membrane and probed with
anti-GFP rabbit polyclonal antibody (Invitrogen).
Nonradioactive Pulse Labeling. The Click-iT AHA (L-azidohomoalaine) for
nascent protein synthesis kit (Invitrogen) was used for these studies, and
experiments were performed according to the manufacturer’s recom-
mendations. Briefly, cells were seeded into 6-cm plates and allowed to grow
to 80–90% confluency. Cells were starved with methionine-free media for
1 h before incubation with Click-iT AHA containing methionine-free media
for the indicated time (pulse) before harvesting for analysis. Harvested cells
were lysed, cell lysates were labeled with biotin-conjugated alkyne, and
biotin-labeled proteins were immunoprecipitated with streptavidin beads
and further analyzed by Western blotting.
Real-Time PCR. RNA was extracted using the TRIzol (Invitrogen) method
according to the manufacturer’s protocol. Following DNase digestion
(Ambion), 1 μg of RNA was transcribed into cDNA in a 20-μL reaction (Ap-
plied Biosystems). cDNA was analyzed and amplified using the ABI 7900HT
system (Applied Biosystems). PCR assays were performed in a 10-μL reaction
containing 2.5 μL of cDNA (1:20 diluted), 100 nM primer (each primer), and
1× SYBR Green PCR Master Mix (Applied Biosystems). The expression level of
TATA-binding protein (TBP) was used as an internal control. Cycle threshold
(Ct) values were used to calculate the amount of amplified PCR product in
comparison to the housekeeping gene, TBP. The results are expressed as the
fold change in mean ± SEM. The relative amount of each transcript was
analyzed using the 2-ΔC(t) method. Statistical differences between mRNA
levels were determined using the nonparametric Student’s t test. A two-
sided P value <0.05 was considered significant.
Primers used were as follows: TGGCTTCTTCTACACACCCAAG and ACAA-
TGCCACGCTTCTGCC for mature insulin 2 mRNA, GGGGAGCGTGGCTTCTTCTA
and GGGGACAGAATTCAGTGGCA for insulin 2 pre-mRNA, ACCCTTCACCA-
ATGACTCCTATG and ATGATGACTGCAGCAAATCGC for TBP, CCTCCTACAG-
CAGTGGTGATTACA and GGGTCTCTGTGCAGTCATTGT for PC1, AGACAATG-
GGAAGACGGTTG and TTGAAGCATAGCCGTCACAG for PC2, GCTCAGGTAA-
TTGAAGTCTT and TACTGCTCACGAATACAGTT for CPE, CCTGTTGGTGCACT-
TCCTA and TCTGAAGGTCCCCGGGGCT for insulin 1, TGGTGCTCATCTCGTC-
AGAG and TGAATTTGAGAGGCATGCTG for glucagon, AATGACATGAAGG-
AGGCAGTAC and GTGTTTCATACAGCCCTTGATAG for eIF4G1, TCCCAAACA-
GAAGGAGGATG and CATTCCGAGGAGAGCTTTTG for IRS1, AGGCAGCGGC-
AGGTACCTCAG and GTCATGGGCATGTAGCCATCA for IRS2, GGCCGAGATG-
TGCGAACT and TTGTTGATGAGCTGGAGCATGT for SREBP1a, GAGCCATGG-
ATTGCACATTT and CTCAGGAGAGTTGGCACCTG for SREBP1c, ATGACCCTG-
ACTGAAAGGCTTCGT and TAACCCTTCACAGGCGTGGAGAAT for SCAP, TC-
ACAGTGACTGAGCTTCAGCA and TCATCTTCATCACACCCAGGAC for Insig1,
and CCGGGCAGAGCTCAGGAT and GAAGCAGACCAATGTTTCAATGG for
Insig2b. ER stress was determined using the following primers: TTCAGCCA-
ATTATCAGCAAACTCT and TTTTCTGATGTATCCTCTTCACCAGT for BiP, CCA-
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Fig. 6. (A) Schematic depicts a potential role for insulin signaling in the
regulation of translation initiation, proinsulin processing, and ER stress. (B)
Hypothetical model shows an early rise in circulating proinsulin levels due to
dysfunctional growth factor (insulin) signaling in β cells and ER stress, to-
gether contributing to progressive β-cell failure and the development of
overt T2D.
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TGGCCGGGTCTGCTGAGTCCG and GTCCATGGGAAGATGTTCTGG for
total XBP-1; and CTGAGTCCGAATCAGGTGCAG and GTCCATGGGAAGAT-
GTTCTGG for spliced XBP-1.
For degradation experiments, cells were incubated with 100 μg/mL Acti-
nomycin D to inhibit transcription and harvested at 0, 30, and 60 min. Insulin
pre-mRNA and mature RNA were determined by generating specific primer
sets that amplify segments of exons to measure spliced and unspliced mRNA
(i.e., total mRNA). Those primer sets that amplify segments of introns only or
intron/exon boundaries were considered unspliced mRNA (i.e., pre-mRNAs).
Reexpression of IRs in βIRKO Cells. Human IR B isoform was stably introduced
into βIRKO cells by retroviral infection. Plates of Phoenix cells were tran-
siently transfected with the retroviral expression vector system pBABE con-
taining human IR cDNA or with empty pBABE vectors (mock controls) using
lipofectamine (Invitrogen). After removing the transfection reagent, cells
were kept for 48 h at 32 °C. The virus containing supernatant was then re-
moved, filtered, and used to infect cells. After overnight infection, cells were
kept in selection media containing 400 μg/mL Hygromycin B.
Lentiviral Knockdown in β Cells. Mouse proinsulin, IR, and SREBP1 shRNA
lentivirus construct were obtained from the University of Massachusetts RNAi
Core Facility (RNAi Consortium library) or Open Biosystems. Lentivirus par-
ticles were generated according to the supplier’s recommendations (Open
Biosystems). βIRKO cells were plated 24 h before infection with virus par-
ticles. Seventy-two hours after infection, cells were harvested for RNA and
subjected to protein analyses.
Reexpression of CPE in βIRKO Cells. Human CPE was subcloned from pCMV6-
XL5 (Origene) into pCDH-CMV-MSC-EF1-GreenPuro lentiviral vector (System
Biosciences). Lentivirus particles were generated according to the manu-
facturer’s recommendations. βIRKO cells were plated 24 h before infection
with virus particles. Seventy-two hours after infection, cells were harvested
for RNA and protein analyses.
Reexpression of Pdx1 or eIF41 in βIRKO Cells. Mouse complete Pdx1 or eIF4G1
ORF was amplified from MIN6 cDNA with PCR using oligos from Integrated
DNA Technologies and cloned into pCDH-CMV-MSC-EF1-GreenPuro lentiviral
vector. Lentivirus particles were generated according to the manufacturer’s
recommendations (System Biosciences). βIRKO cells were plated 24 h before
infection with virus particles. Seventy-two hours after infection, cells were
harvested for RNA and protein analyses.
Proinsulin and Insulin Measurement. Cells or islets were extracted with acid
ethanol [18% (vol/vol) 1N HCl, 75% (vol/vol) ethanol, 7% (vol/vol) H2O] so-
lution for 16 h at 4 °C. The proinsulin (Alpco) and insulin (Linco) concen-
tration was measured by ELISA. The proinsulin and insulin content was
normalized to the total DNA content. For HPLC analyses, size-matched iso-
lated islets were subjected to incubation with 100 mCi of [3H]-leucine in
KREB ringer buffer (64) at 37 °C for 1 h. Islets were then extracted with 100
mM HCl and sonicated. Extracted cell lysates were applied to Altima Reverse-
Phase C18 (5-μm) HPLC columns with a Beckman–Coulter HPLC System Gold
(islets core facility, The University of Chicago). Protein fractions were eluted
and quantified.
Polyribosomal Profiling and Gradient Fraction Quantitative PCR. For poly-
ribosomal profiling studies, βIRKO cells and control cells were lysed and
processed for polyribosomal profile analysis on sucrose gradients as de-
scribed previously (65). A piston gradient fractionator (BioComp) was used to
measure RNA A254 with an in-line UV monitor, and gradients were collected
in ten 1-mL fractions. Fractions 1–5 were combined as the monosome pool,
and fractions 6–10 were combined as the polysome pool. RNA was isolated
from each pool using the Qiagen RNeasy Plus Mini Kit and subjected to
quantitative real-time RT-PCR using SYBR-Green methodology. The per-
centage of message recovered in the monosome and polysome pools was
determined for each condition.
ChIP. Briefly, ∼500 islets from 8-wk-old male CD1 mice were isolated, fixed in
1% formaldehyde, and quenched in glycine. Islets were washed with PBS and
lysed in 100 μL of cold lysis buffer [10 mM Tris·HCl (pH 8.0), 10 mM NaCl, 3 mM
MgCl2, 1% Nonidet P-40, 0.1% SDS, 0.5% deoxycholic acid] with protease and
phosphatase inhibitors (Calbiochem) for 10 min. Islets were then sonicated
with a Diagenode bioruptor (30-s on/off pulses for a total of 15 min). Immu-
noprecipitations were performed as previously described (66) using a goat
anti-Pdx1 antiserum (kindly provided by C. Wright, Vanderbilt University,
Nashville, TN). The ChIP PCR was done with the following primers: eIF4G1 5′F,
CCGGAAATGGTTGTGGACTA; eIF4G1 5′R, CGGACATGGCGGCTTTA; eIF4G1 3′F,
AATGACTGCATGGTCTACCG; eIF4G1 3′R, GGCAAGCCTACGTCACAG; Alb F,
TGGGAAAACCATCCTATCAAA; and Alb R, CACCTCTTTGTTGTTTCCTTCTG.
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